NYSE American · Biotechnology · USD
Impact BioMedical Inc. (IBO) Stock Analysis
Impact BioMedical Inc. (IBO) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
IBO Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.60
- Previous Close
- $3.27
- Day's Range
- 3.60–4.24
- 52-Week Range
- 2.43–10.51
- Volume
- 26.23K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.73
Valuation
- Market Cap
- $34.35M
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 981.30
Financials (FY)
- Revenue (FY)
- $32.00K
- Net Income (FY)
- −$11.84M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 2,260.00%
- Shares Outstanding
- 8.54M
- 1-Year Return
- −45.71%
Dividend and dates
- Avg Volume
- 13.46K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, IBO closed at $4.02, −45.71% over 1 year.
Impact BioMedical Inc. (IBO) has a market capitalization of $34.35M.
In fiscal 2025, IBO reported revenue of $32.00K.
IBO Stock Return by Calendar Year
Impact BioMedical Inc. (IBO) return since Sep 2024: what $10,000 became
- 1 year
- $10,000 $5,429
- −45.71%
- Since Sep 2024
- $10,000 $1,185
- −88.15%
If you had invested $10,000 in Impact BioMedical Inc. (IBO) at the close on September 16, 2024, the earliest close on record here, it would have been worth $1,185 at the close on October 21, 2026: −88.15% in total, −63.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −37.11% |
| 2025 | −65.17% |
| 2024 (partial year) | −45.90% |
As of October 21, 2026.
IBO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $32.00K | −$11.84M | −36,993.8% |
| 2024 | $0.00 | −$24.71M | — |
| 2023 | $0.00 | −$4.34M | — |
| 2022 | $50.00K | −$7.05M | −14,102.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $32.00K | −$392.00K | −$4.27M | −$11.84M | −36,993.8% |
| 2024 | $0.00 | $0.00 | −$3.40M | −$24.71M | — |
| 2023 | $0.00 | — | −$4.03M | −$4.34M | — |
| 2022 | $50.00K | — | −$3.40M | −$7.05M | −14,102.0% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
IBO Valuation vs Biotechnology Median
Median of 608 stocks| Metric | IBO | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 981.30 | 13.30 | 73.8x the median |
| Profit margin | 2,260.00% | −38.31% | 2,298.3 pts above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
YahooImpact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
YahooCORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
YahooImpact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
YahooImpact BioMedical Announces 1-For-12.62 Reverse Stock Split, Reducing Shares Outstanding From ~107.8M To ~8.54M, Effective Sept. 23
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B